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Background: HIV infection leads to a decreasing immune response, thereby facilitating the appearance of other
infections, one of the most important ones being HPV. However, studies are needed for determining associations
between immunodeficiency caused by HIV and/or the presence of HPV during the course of cervical lesions and
their degree of malignancy. This study describes the cytological findings revealed by the Papanicolaou test,
laboratory characteristics and HPV molecular profile in women with and without HIV infection.
Methods: A total of 216 HIV-positive and 1,159 HIV-negative women were invited to participate in the study;
PCR was used for the molecular detection of HPV in cervical samples. Statistical analysis (such as percentages,
Chi-square test and Fisher’s exact test when applicable) determined human papillomavirus (HPV) infection
frequency (single and multiple) and the distribution of six types of high-risk-HPV in women with and without
HIV infection. Likewise, a logistic regression model was run to evaluate the relationship between HIV-HPV
infection and different risk factors.
Results: An association was found between the frequency of HPV infection and infection involving 2 or more
HPV types (also known as multiple HPV infection) in HIV-positive women (69.0% and 54.2%, respectively); such
frequency was greater than that found in HIV-negative women (44.3% and 22.7%, respectively). Statistically
significant differences were observed between both groups (p = 0.001) regarding HPV presence (both in
infection and multiple HPV infection). HPV-16 was the most prevalent type in the population being studied (p = 0.001);
other viral types had variable distribution in both groups (HIV-positive and HIV-negative). HPV detection was associated
with <500 cell/mm3 CD4-count (p = 0.004) and higher HIV-viral-load (p = 0.001). HPV-DNA detection, <200 cell/mm3
CD4-count (p = 0.001), and higher HIV-viral-load (p = 0.001) were associated with abnormal cytological findings.
Conclusions: The HIV-1 positive population in this study had high multiple HPV infection prevalence. The results for this
population group also suggested a greater association between HPV-DNA presence and cytological findings.
HPV detection, together with low CD4 count, could represent useful tools for identifying HIV-positive women
at risk of developing cervical lesions.
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Epidemiological and molecular studies have led to a causal
relationship being established between infection involving
certain types of human papillomavirus (HPV), known
as high risk (HR-HPV), and the development of
cervical cancer (CC) [1]. Fifteen of the viral types
identified to date have been classified as HR-HPV (HR-
HPV-16, −18, −45, −31, −33, −52, −58 and −35 having
the highest frequency) [1].
This type of cancer accounts for the second cause of
death by malignant neoplasia in women, primarily those
of childbearing age and living in developing countries. A
CC mortality rate of 18.2 for every 100,000 women per
year was reported in Colombia in 2010 [2].
HPV infection (considered a common sexually-
transmitted infection) is necessary but not the sole factor
for CC to develop; several risk factors can trigger the devel-
opment of this cancer, immunosuppression being one of
the most significant ones [3-5].
One of the most studied types of immunosuppression
is that due to human immunodeficiency virus (HIV)
infection [6]. Such infection leads to alterations in cell-
mediated immunity, thereby facilitating the acquisition
of opportunistic infections and limiting an organism’s
ability to produce an efficient immune response [7].
Higher HPV infection prevalence has been docu-
mented in HIV-infected women; the foregoing, taken
together with a deficient immune system, thus contrib-
utes towards new infections involving other HPV types
being acquired (multiple infection or the coexistence
of 2 or more HPV types) which, as the virus cannot be
eliminated, increases HPV infection persistence in the
body [5,8].
The clinical significance of HPV persistence concerns this
virus’ long-term existence. This allows for the efficient rep-
lication and integration of viral oncoproteins (E6 and E7) in
the host genome, mutations to become accumulated, gen-
omic instability and chromosomal aberrations; this causes
rapid morphological changes to cells, thereby contributing
towards CC development [9,10].
Mild dysplasia prevalence in immunocompetent women
does not exceed 27%, whereas this can rise to 80% in
HIV-positive women; immunosuppression in the latter
group implies the development of more aggressive le-
sions and a lower response to treatment [11], as well as
leading to the appearance of precancerous lesions in
about 60% of women suffering HPV infection which
evolves in less than 3 years [11,12].
It has been described that HIV-positive women having
a CD4 count of less than 200 cells/mm3 have greater
HPV infection prevalence and increased cervical intrae-
pithelial lesion incidence rates; the foregoing, together
with a high HIV viral load, significantly increases the risk
of developing this type of lesion [13].It has been stated that the relationship between HIV-
HPV might become a worldwide public health problem
[14]; however, some reports have shown a low correlation
between HIV infection and the development of neoplastic
lesions. Such correlation mainly occurs in low-income
countries having limited access to antiretroviral therapy
(ART) [10,15].
No studies have been carried out to date in Colombia
to determine HIV-HPV infection-related epidemiological
profiles, so this study was aimed at describing the preva-
lence of multiple HPV infection, involving the type-specific
distribution of six HR-HPV types amongst women with
and without HIV infection involved in sexual and repro-
ductive health programmes at four hospitals in Bogota. The
resulting information has contributed towards knowledge
regarding HIV-HPV-related sexually-transmitted infections.Methods
Study design
This was a cross-sectional study; the patients partici-
pated between February 2007 and November 2012. All
hospitals included in this study are located in the country’s
capital city, Bogotá. The group of HIV-positive women
(classified as having human immunodeficiency virus type 1)
were attending a programme being run by Asistencia
Científica de Alta Complejidad S.A.S (n = 216). The
HIV-negative women were participating in sexual and
reproductive health programmes being provided by
state-run healthcare institutes; this group of women
was recruited at the Hospital de Bosa (n = 232), Hospital de
Fontibón (n = 290) and the Hospital de Engativá (n = 637),
all located in Bogotá. The participating institutions reported
the HIV status for all the women included in the study.
All the women were told about the study’s purpose.
Those who volunteered to participate signed an informed
consent form and completed a questionnaire aimed at col-
lecting data concerning socio-demographic characteristics
and risk factors before being given a gynaecological exam.
An informed consent form, signed and approved in the
presence of a parent or guardian, was required for women
younger than 18 years old. This study was approved and
supervised by all health care participating institutions’
Ethics Committees as follows: the Bioethics Committee
of ‘Asistencia Científica de Alta Complejidad’, the Ethics
Committee of the ‘Hospital de Bosa E.S.E.’, the Ethics
Committee of the ‘Hospital de Fontibón E.S.E.’, and the
Hospitalary Ethics Committee of the ‘Hospital de Engativá
Nivel II’.
The inclusion criteria took into account the HIV status
reported by the participating institutions, the women’s
voluntary participation in this study by signing the con-
sent form and filling in a questionnaire which consid-
ered socio-demographic characteristics and risk factors.
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gene segment could not be amplified.
Sample collection and methodological design
Papanicolaou test (Pap test) samples were collected fol-
lowing Colombian Ministry of Health guidelines for the
early detection of CC [16]; the Pap smears were read by
each participating hospital. Cytological findings were re-
ported according to the Bethesda system as being atypical
squamous cells of undetermined significance (ASCUS), a
low grade squamous intraepithelial lesion (LSIL) or a high
grade squamous intraepithelial lesion (HSIL).
Cervical samples for detecting HPV-DNA were ob-
tained during cytological exam; cells were collected from
the cervix using a cytobrush which was stored in a tube
containing 95% ethanol as a means of preservation and
transport [17].
The methodological design for detecting HPV involved
using PCR, firstly, directed towards determining DNA
quality and integrity (using primers directed towards de-
tecting the β-globin gene segment). Independent PCRs
were then used for the generic detection of HPV, using
three sets of primers directed towards detecting seg-
ments encoding viral proteins L1 and E6-E7. Independ-
ent PCRs were also used on samples where generic
detection had revealed the virus; type-specific identifica-
tion involved using primers directed towards genes en-
coding early proteins E5, E6 and E7 [17,18].
Sample processing and human papillomavirus DNA
detection
Total DNA was extracted from cervical cells using a
commercial QuickExtract solution kit (Epicentre, Madi-
son, WI), following the manufacturer’s instructions.
PCR analysis involved GH20/PC04 and PC03/PC04
specific primers for detecting a β-globin gene segment in
independent PCR reactions to confirm the presence of
human DNA in all the samples [17].
Established PCR techniques were used for HPV-DNA
detection [17,18]. Viral genes were detected using three
primer sets; pU1M/2R was directed to the region encod-
ing virus oncogenic proteins (E6/E7) and GP5+/6+ and
MY09/11 directed towards a segment encoding the L1
late protein [17].
Samples having a positive result for HPV-DNA by
PCR (samples proving positive for one or more of the
three generic primer sets) were used for type-specific
identification using primers targeting regions encoding
viral oncogenic proteins E5, E6 or E7 from six high-risk
HPV types (HR-HPV-16, −18, −31, −33, −45, −58), these
being the most prevalent in the Colombian population
and accounting for 90% of CC cases [17].
All PCRs were run simultaneously in separate reac-
tions and in previously described conditions [17,18].Statistical analysis
Sample size was determined as being 179 in the HIV-
positive group and 716 for the HIV-negative group to
ensure 80% power for detecting a 1.60 odds ratio (OR).
The proportion in group one (HIV-positive women) was
assumed to be 0.45 by null hypothesis and 0.55 by alter-
native hypothesis.
A descriptive analysis of the demographic characteris-
tics and risk factors was made and they were treated as
categorical variables (mean, standard deviation (SD),
percentages); estimations were made, along with their
respective 95% confidence intervals (95% CI). Chi-square
and Fisher’s exact tests were used (when applicable) to
evaluate differences in proportions. The coexistence of 2
or more HPV types was defined as multiple infection in
this study. The strength of association was measured
using ORs with 95% CI; logistic regression was used for
ordinal data to estimate adjusted ORs. The cofactors in-
cluded in regression analysis were age, marital status,
age at first intercourse, number of pregnancies, having
had other STDs, the number of lifetime sexual partners,
contraceptive methods used and smoking status, along
with laboratory characteristics (Papanicolaou test, CD4-
count, HIV-viral-load and ART). All hypothesis tests
were set at 0.05 significance level. STATA11 was used
for all statistical procedures.Results
The study involved 1,375 women aged 14–76 years
(SD = 10.9; mean age = 36.9: 36.3-37.5 95% CI). The
predominant ethnic group consisted of 1,337 mestizo
women (97.2%: 96.2-98.1 95% CI), the remaining 38
(2.8%: 1.92-3.65 95% CI) being Afro-descendants and
indigenous females.
216 of the women were HIV-positive whose ages
ranged from 20–73 years old (SD = 10.7; mean age =
37.5: 36.0-38.9 95% CI) and a second group consisted of
1,159 HIV-negative women aged 14–76 (SD = 11.0; mean
age = 36.8: 36.1-37.4 95% CI). The estimator revealed sta-
tistically significant differences regarding some women’s
socio-demographic characteristics and risk factors accord-
ing to HIV status (such as ethnicity and age at first inter-
course), whilst no statistically significant difference was
recorded for pregnancies (p = 0.173) and/or infection with
other sexually transmitted diseases (p = 0.071) (Table 1).
All samples (n = 1,375) which amplified for the β-globin
gene and tested for HPV-DNA presence (indicated by posi-
tive amplification of pU1M/2R, GP5+/6+ or MY09/11, or
more than one) were used in the statistical analysis. The
virus was detected in 48.1% of the samples (n = 662: 45.5-
50.8 95% CI) and multiple infection (defined as coexistence
of 2 or more HPV types) in 57.4% (n = 380: 53.5-61.7 95%
CI) of HPV positive samples.
Table 1 Demographic profile of the 1,375 women having positive human β-globin amplification
Variable HIV-positive HIV-negative p value
(n = 216) (n = 1,159)
Age* 37.5 [20–73] 36.8 [14–76]
SD = 10.7 SD = 11.0
Ethnicity n (%) n (%)
Indigenous 3 (1.4) 2 (0.2)
Mestizo 209 (96.8) 1,128 (97.3)
Afro-descendant 4 (1.8) 29 (2.5) 0.021
Marital status
Single 66 (30.6) 301 (26.0)
Married 36 (16.7) 202 (17.4)
Cohabiting 65 (30.1) 497 (42.9)
Separated 22 (10.2) 132 (11.4)
Widowed 27 (12.4) 27 (2.3) 0.001
Age at first intercourse
<15 75 (34.7) 276 (23.8)
16-19 111 (51.4) 618 (53.3)
>19 30 (13.9) 265 (22.9) 0.001
Pregnancies
None 10 (4.6) 69 (6.0)
1-3 160 (74.1) 784 (67.6)
>4 46 (21.3) 306 (26.4) 0.173
Abortions
No 120 (55.7) 741 (64.0)
Yes 96 (44.3) 418 (36.0) 0.019
Other STD
No 136 (63.0) 653 (56.4)
Yes 80 (37.0) 506 (43.6) 0.071
Lifetime number of sexual partners
1-2 88 (40.7) 783 (67.5)
>3 128 (59.3) 376 (32.5) 0.001
Contraceptive method
None 43 (19.9) 337 (29.1)
Hormonal 11 (5.1) 189 (16.3)
Surgery 46 (21.3) 318 (27.4)
Condom 97 (45.0) 113 (9.8)
Intrauterine device 19 (8.7) 202 (17.4) 0.001
Smoking status
No 177 (81.9) 776 (66.9)
Yes 39 (18.1) 383 (33.1) 0.001
Cytological findings
Normal 148 (68.5) 918 (79.2)
Abnormal 68 (31.5) 241 (20.8) 0.006
p value: Probability value, SD: standard deviation, STD: sexually transmitted diseases.
*Mean [range]; SD.
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HIV-negative women (n = 513: 41.4-47.2 95% CI) and
multiple infection in 51.3% of them (n = 263: 46.8-55.7
95% CI). The presence of HPV was observed in 69.0% of
HIV-positive women (n = 149: 62.3-75.0 95% CI) and
multiple infection was found in 78.5% of the sample (n =
117: 71.0-84.8 95% CI). Statistically significant differences
were observed between both groups of women (p = 0.001)
regarding HPV presence (both in infection and multiple
HPV infection).
Cytological findings proved negative for intraepithelial
lesions or malignancy in 68.5% of the HIV-positive
women (n = 148: 61.9-74.7 95% CI) and abnormality oc-
curred in 31.5% of them (n = 68: 25.3-38.1 95% CI), classi-
fied as follows: ASCUS occurred in 35.3% of cytological
abnormalities (n = 24: 24.1-47.8 95% CI), LSIL in 57.3%
(n = 39: 44.8-69.3 95% CI) and HSIL in 7.4% of them (n = 5:
2.4-16.3 95% CI).
79.2% (n = 918: 76.7-81.5 95% CI) of HIV-negative
women proved negative for lesions, whilst 20.8% of them
(n = 241: 18.5-23.2 95% CI) had some degree of abnor-
mality: 52.7% (n = 127: 46.2-59.1 95% CI) had ASCUS,
41.5% (n = 100: 35.2-47.9 95% CI) had LSIL and 5.8%
(n = 14: 3.21-9.55 95% CI) HSIL. The difference between
abnormality detected by Pap test for women having dif-
ferent HIV infection status was statistically significant
(p = 0.003).
Association between HPV status and Pap test result
determined by ORs revealed a positive trend for HPV-
DNA detection and ASCUS cytological findings (crude
OR 1.85: 1.31-2.63 95% CI). A positive association was
observed when comparing SIL cytological findings
(crude OR 1.70: 1.21-2.39 95% CI; test of trends in odds:
Chi2 (1) = 16.13 p = 0.001). Calculating regression analysis
association between HIV status and Pap test result revealed
a positive trend for HIV-positive and SIL (crude OR 2.39:
1.61-3.54 95% CI; test of trends in odds: Chi2 (1) = 18.04
p = 0.001). All associations remained statistically significant
after using logistical regression to adjust for cofactors (de-
scribed in the statistical analysis section) (Table 2).Table 2 Multivariate analysis of HPV status and HIV status in
HPV status
Negative Positive Adjusted O
(95% CI)Pap test result n (%) n (%)
Negative 587 (82.3) 479 (72.4) Ref
ASCUS 60 (8.4) 91 (13.7) 1.84 1.28
SIL* 66 (9.3) 92 (13.9) 1.69 1.19
Total 713 662
OR adjusted for age, marital status, age at first intercourse, the number of lifetime s
test, CD4-count, HIV-viral-load and antiretroviral therapy or ART.
95% CI: confidence interval, OR: odds ratio, ASCUS: atypical squamous cells of unde
Values in bold = p < 0.05.
*SIL include: low grade squamous intraepithelial lesion (LSIL) and high grade squamPositive associations (using regression analysis) between
abnormal cytological findings (including ASCUS, LSIL and
HSIL) and clinical and laboratory characteristics (CD4
count, HIV viral load and antiretroviral therapy-ART)
showed a positive trend for CD4 cell count below 200 cell/
mm3 (crude OR 2.96: 1.85-4.73 95% CI; test of trends in
odds: Chi2 (1) = 23.03 p = 0.001), higher than 100,000
copies/mL HIV viral load (crude OR 10.47: 3.26-33.60
95% CI; test of trends in odds: Chi2 (1) = 23.40 p =
0.001) and women with and without ART treatment
(crude OR 1.57: 1.11-2.21 95% CI, and crude OR 4.19:
1.75-10.03 95% CI; test of trends in odds: Chi2 (1) =
15.96 p = 0.001) (Table 3).
ORs were used for assessing the association between
women with and without HIV infection and having HPV
(prevalence, infection status, clade detected and clinical
and laboratory characteristics). The results revealed sta-
tistically significant associations between HIV-positive
women and an increased likelihood of HPV-DNA detection
(crude OR 2.80: 2.04-3.84 95% CI; p = 0.001), multiple in-
fection (crude OR 4.02: 2.94-5.49 95% CI; p = 0.001), clade
7 (crude OR 2.62: 1.90-3.62 95% CI; p = 0.001) and clade 9
detection (crude OR 2.91: 2.14-3.97 95% CI; p = 0.001),
lower than 500 cell/mm3 CD4 cell count (crude OR 2.02:
1.11-3.70 95% CI; p = 0.004), higher than 100,000 copies/
mL HIV viral load (crude OR 8.18: 1.82-36.71 95%C; p =
0.001) and women with and without ART treatment (crude
OR 2.68: 1.93-3.72 95% CI; p = 0.001 and crude OR 3.52:
1.25-9.88 95% CI; p = 0.005). These associations remained
significant in multivariate analysis (Table 4).
Regarding type-specific distribution in HIV-positive and
negative groups, HPV-16 was the most prevalent infection
for the entire study population (p = 0.001). Significant dif-
ferences were observed regarding the percentages of HPV
infection types for each population, HPV-31 was the second
most prevalent in HIV-positive women (p = 0.001), HPV-18
the third (p = 0.001) (Table 5) whilst HPV-58 was the sec-
ond most prevalent in HIV-negative women (p = 0.215)
followed by HPV-31 (p = 0.001). HPV-45 occurred least fre-
quently in both populations (p = 0.001) (Table 5).women regarding cytological findings
HIV status
R Negative Positive Adjusted OR
(95% CI)n (%) n (%)
918 (79.2) 148 (68.5) Ref
-2.62 127 (11.0) 24 (11.1) 1.18 0.70-1.99
-2.41 114 (9.8) 44 (20.4) 2.74 1.74-4.33
1,159 216
exual partners, contraceptive methods used and smoking status, Papanicolaou
termined significance, SIL: squamous intraepithelial lesions.
ous intraepithelial lesions (HSIL).
Table 3 Multivariate analysis of factors associated with abnormal cytological findings
Abnormal Pap test result *
n (%)** Adjusted OR 95% CI
HIV; immune status CD4 cell/mm3 count
HIV-negative 241 (20.8) Ref
HIV-positive, < 200 35 (16.2) 2.89 1.73-4.84
HIV-positive, 200 - 349 12 (5.6) 1.05 0.52-2.11
HIV-positive, 350 - 500 12 (5.6) 1.34 0.66-2.71
HIV-positive, > 500 9 (4.2) 1.41 0.63-3.16
HIV viral load copies/mL
HIV-negative 241 (20.8) Ref
HIV-positive, <4,000 49 (22.7) 1.44 0.96-2.16
HIV-positive, 4,000-99,999 8 (3.7) 1.95 0.77-4.94
HIV-positive, >100,000 11 (5.1) 8.63 2.65-28.12
HIV and ART use
HIV-negative 241 (20.8) Ref
HIV-positive, treatment with ART 57 (26.4) 1.57 1.06-2.32
HIV-positive, without treatment with ART 11 (5.1) 3.63 1.39-9.45
OR adjusted for age, marital status, age at first intercourse, the number of lifetime sexual partners, contraceptive methods used and smoking status, Papanicolaou
test, CD4-count, HIV-viral-load and antiretroviral therapy or ART.
Values in bold = p < 0.05.
Pap test: Papanicolaou test, 95% CI: confidence interval, OR: odds ratio, HIV: Human Immunodeficiency Virus, ART: antiretroviral therapy, ASCUS: atypical
squamous cells of undetermined significance, LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesions.
*Includes ASCUS, LSIL and HSIL.
**Percentages were calculated regarding HIV-positive = 216 and HIV-negative n = 1,159.
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type distribution regarding 200 to 349 cell/mm3 CD4
count; HPV-18 had the greatest prevalence (p = 0.041),
followed by HPV-16 (p = 0.241) and HPV-31 (p = 0.008).
Other differential distributions were observed for higher
than 100,000 copies/mL HIV viral load; however, they
were not statistically significant (Table 5).
Discussion
HPV infection and multiple infection prevalence was
found to be similar to that reported for Colombia in pre-
vious studies concerned with the heterogeneous female
population [17].
HPV prevalence in the HIV-positive population was
significantly higher than in the group of HIV-negative
women. This agreed with other studies which found that
HIV-related immunosuppression disabled an immune
system response to concomitant infection [4,19].
High HPV infection prevalence in HIV-positive women
has been reported in worldwide studies; there is 44% HPV
infection in European countries such as Italy [5] and US
studies have found 54%-73% prevalence [20,21], similar to
that for Latin-American countries like Brazil where 48%
to 68% HPV prevalence has been found in HIV-positive
women [22,23].
Our results showed that multiple HPV infection occurred
more frequently in HIV-positive women; this may havebeen due to a deficient immune system [7], risky sexual
behaviour engaged in by this particular group involving an
increased exposure risk and higher reactivation rates re-
garding latent HPV infection [7,19], Furthermore, it has
been reported that the risk of acquiring later HPV infection
becomes increased in HPV-infected women, which could
contribute to high multiple infection frequency [24].
Some studies have shown the co-existence of more
than one HPV type in the same organism [25]; however,
the clinical relevance of being infected with multiple
HPV types has not been clearly established. Multiple in-
fection results have indicated that HPV facilitates per-
sistence at the site of infection, leading to an increased
risk of premalignant lesions progressing to CC [24,26].
Type-specific distribution revealed that HPV-16 was
the most prevalent type in the population being studied;
this was consistent with worldwide results to date
[17,27,28]. High prevalence was found for the other
HPV types being tested, such as HPV-31 in HIV-positive
women and HPV-58 in the group of HIV-negative fe-
males; these viral types have been reported in Colombia
in previous studies by our research group and others
working in the field as being the most prevalent [17,29].
Such differential type distribution between groups
(HIV-positive and HIV-negative) may have been partly
due to immune system deficiency, thereby contributing
towards the inefficient removal of the virus or evasion
Table 4 Relative frequency and multivariate analysis of HPV infection in HIV- negative and HIV- positive women
HPV positive detection
n (%)* Adjusted OR 95% CI
HIV status
Negative 513 (44.3) Ref
Positive 149 (69.0) 2.37 1.69-3.34
HIV and one type only HPV (single infection)
HIV-negative, single infection 250 (21.6) Ref
HIV-positive, single infection 32 (14.8) 1.14 0.85-1.28
HIV and >1 type HPV (multiple infection)
HIV-negative, multiple infection 263 (22.7) Ref
HIV-positive, multiple infection 117 (54.2) 3.43 2.39-4.92
HIV and HPV Clade 7
HIV-negative, HPV Clade 7 202 (17.4) Ref
HIV-positive, HPV Clade 7 77 (35.7) 2.48 1.69-3.64
HIV and HPV Clade 9
HIV-negative, HPV Clade 9 454 (39.2) Ref
HIV-positive, HPV Clade 9 141 (65.3) 2.47 1.73-3.53
HIV; immune status CD4 cell/mm3 count
HIV-negative 513 (44.3) Ref
HIV-positive, < 200 63 (29.2) 4.38 2.47-7.77
HIV-positive, 200 - 349 39 (18.1) 3.13 1.64-5.96
HIV-positive, 350 - 500 29 (13.4) 1.91 1.03-3.57
HIV-positive, > 500 18 (8.3) 1.17 0.59-2.32
HIV viral load copies/mL
HIV-negative 513 (44.3) Ref
HIV-positive, <4,000 121 (56.0) 2.41 0.67-3.48
HIV-positive, 4,000-99,999 15 (6.9) 2.43 0.96-6.14
HIV-positive, >100,000 13 (6.0) 7.32 1.62-33.03
HIV and ART use
HIV-negative 513 (44.3) Ref
HIV-positive, treatment with ART 133 (61.6) 2.46 1.72-3.51
HIV-positive , without treatment with ART 16 (7.4) 3.32 1.16-9.50
OR adjusted for age, marital status, age at first intercourse, the number of lifetime sexual partners, contraceptive methods used and smoking status, Papanicolaou
test, CD4-count, HIV-viral-load and antiretroviral therapy or ART. Abbreviations: 95% CI: confidence interval, OR: odds ratio, HIV: Human Immunodeficiency Virus,
ART: antiretroviral therapy, HPV: Human Papillomavirus.
*Percentages were calculated regarding HIV-positive = 216 and HIV-negative n = 1,159.
Clade 7: HPV-18 and −45; Clade 9: HPV-16, −31, −33 and −58. Values in bold = p < 0.05.
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and persistence of some viral types (mainly oncogenic
HPV) [7,8,30].
A positive association was seen in the current study
for women having lower than 200 cell/mm3 CD4 count
with abnormal cytological findings, compared to those
having higher CD4 count, thereby agreeing with a previ-
ous report [5]. Lower than 200 cell/mm3 count indicates
a deficient immune system and, together with HPV de-
tection, could be used as predictors of pre-neoplastic
cervical lesions [31].Our groups’ results showed that a lower than 500 cell/
mm3 CD4 count was associated with HPV detection,
thereby reflecting the inability of HIV-positive women’s
immune systems to respond to opportunist infection.
High HIV viral load and low CD4 cell counts could fa-
cilitate acquiring HPV infection [32,33].
The effect of antiretroviral drugs on the incidence of
cervical lesions having a poor prognosis has not been
clearly established; previous studies, such as the US
WIHS (Women’s Interagency HIV Study) cohort, have
indicated that ART treatment for HIV positive women




HPV-16 HPV-18 HPV-31 HPV-33 HPV-45 HPV-58
HIV-positive (n = 216) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
149 69.0 100 46.3 66 30.6 71 32.9 40 18.6 19 8.8 44 20.4
CD4 cell/mm3 count
< 200 63 29.2 44 20.4 22 10.2 35 16.2 13 6.0 9 4.2 18 8.3
200 - 349 39 18.1 22 10.2 18 8.3 19 8.8 15 6.9 5 2.3 14 6.5
350 - 500 29 13.4 18 8.3 20 9.3 12 5.6 10 4.6 3 1.4 8 3.7
> 500 18 8.3 16 7.4 6 2.8 5 2.3 2 0.9 2 0.9 4 1.9
HIV viral load copies/mL
<4,000 121 56.0 82 38.0 54 25.0 54 25.0 33 15.3 15 6.9 32 14.8
4,000-99,999 15 6.9 11 5.1 9 4.2 10 4.6 4 1.9 1 0.5 8 3.7
>100,000 13 6.0 7 3.2 3 1.4 7 3.2 3 1.4 3 1.4 4 1.9
ART use
Yes 133 61.6 90 41.7 61 28.2 64 29.6 36 16.7 18 8.3 39 18.1
No 16 7.4 10 4.6 5 2.3 7 3.2 4 1.9 1 0.5 5 2.3
HIV-negative (n = 1,159)
513 44.3 222 19.2 118 10.2 151 13.0 104 9.0 98 8.5 177 15.3
HIV: Human Immunodeficiency Virus, ART: antiretroviral therapy, HPV: Human Papillomavirus.
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[31]. Our group’s results showed that women with and
without treatment with antiretroviral drugs had a sig-
nificant association with HPV detection and abnormal
cytological findings; this could have been due to high
HPV-16 prevalence, since it has been established that
the effect of therapy involving ART on the appearance
of cervical disease is reduced when infections by this
viral type occur [31].
More lesions were detected in the HIV-positive group
(mainly LSIL); studies have indicated that women having
this type of immunosuppression have a higher incidence
and prevalence of premalignant lesions caused by the
immune system becoming unable to efficiently eliminate
HPV infection. This also favours the virus’ persistence in
the body, ultimately contributing towards the develop-
ment of this type of dysplasia [34,35].
Association studies have shown that HIV infection in-
creases the risk of CC development (up to 22-fold) com-
pared to such risk in the general population [19]. The
natural history of CC development becomes altered in
women having immunosuppression caused by HIV since
the regression of lesions has been seen to decrease sig-
nificantly compared to HIV-negative women [4,36].
This can be explained as immunosuppression leads to an
alteration in local and systemic immune response, thereby
preventing suitable clearance of HPV infection. This results
in recurrent pre-neoplastic lesions and lower regression
rates; however, it has not been clearly established whether
this is the main mechanism [6,13,21].Our results showed a significant association between
infection involving clade 9 and HIV-positive women; this
may have been partly due to HPV-16 in this clade being
the most prevalent viral type in such population. This
viral type has been shown to have an association with
the risk of acquiring other HPV types; however, it has
not been clearly established whether a higher risk of ac-
quiring a phylogenetically-related type is associated with
the risk of acquiring another type of HPV [7,24].
Interestingly, a positive trend was found between ASCUS
cytology and HPV-DNA being detected. ASCUS cytology
indicated that cytological-morphological changes were not
benign; however, this did not meet the criteria for classifica-
tion as squamous lesions, even though studies have shown
that this type of cytological interpretation is highly related
to characteristic subjective reading of Pap tests [37,38].
Studies have found that HPV detection in women having
ASCUS has provided high sensitivity in detecting severe
dysplasia and cancer [39]. This is why strengthening HPV
molecular screening for detecting women having atypical
ASCUS (first indicator of cervical abnormalities) may help
in reducing the impact caused by CC on an immunocom-
petent population, as well as HIV-infected women who are
at increased risk [40].
One of this study’s limitations lay in the detection of 6
of the 15 HPV types described as being high risk. Even
though the types identified in the present study are con-
sidered to be prevalent in the Colombian population,
other types of high and low risk HPV should be included
in future studies. This study’s cross-sectional design did
Camargo et al. BMC Cancer 2014, 14:451 Page 9 of 10
http://www.biomedcentral.com/1471-2407/14/451not lead to determining a causal relationship between
the immunodeficiency caused by HIV and/or the preva-
lence and persistence of HPV.
Conclusions
There is limited information in Colombia regarding
HPV infection in HIV-positive women. This is the first
study in Colombia which has evaluated epidemiological
profiles concerning HPV infection in both HIV-positive
and HIV-negative women. The results further showed
multiple HPV infection as an associated factor in HIV-
positive women; however, further prospective studies are
needed to determine the dynamics and follow-up pat-
terns (i.e. 5-year follow-up) for these infections and their
influence on the development of cervical dysplasia.
HR-HPV distribution in women should be studied to
facilitate developing prevention and management strat-
egies in the general population, prioritising HIV-positive
women as they represent a special group due to their
type of immunosuppression altering the natural course
of CC development. The resulting information has con-
tributed towards knowledge regarding HIV-HPV-related
sexually-transmitted infections.
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